aibioImmunovant
Top story · Sep 3, 2026 · SEC filing 8-K
Immunovant reports shareholder vote results
- Ticker
- IMVT
- Listing
- NASDAQ, United States
- Next date
- Second half of calendar 2026
- Chief executive
- Eric Venker, M.D., Pharm.D.
Desk view · Opinion · Updated Oct 22, 2026
Immunovant is down to one drug and a long wait for proof
Immunovant has cut down to one drug and a clear calendar, with enough cash to reach its 2027 Graves' disease and myasthenia gravis readouts. Two misses in 2026 have weakened the case that deeper IgG lowering always wins. The randomized part of the arthritis trial and the 2027 data will decide whether IMVT-1402 stands apart from approved FcRn drugs.
Read the full desk viewaibio.space Investor Rank · Opinion
3/10 Negative view
Cash reaches the 2027 readouts, but the company is down to IMVT-1402 after a phase 3 miss and a lupus miss, in markets with approved FcRn drugs.
- Technology
- 1/2
- Odds
- 0/2
- Balance sheet
- 1/2
- Risk
- 1/2
- Momentum
- 0/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Mechanism validated, drug not yet. FcRn blockers are approved in myasthenia gravis, but IMVT-1402's only published patient efficacy numbers so far are open-label.
- Odds
- Mixed track record. Batoclimab missed in phase 3 and IMVT-1402 missed in cutaneous lupus, while open-label arthritis data looked strong.
- Balance sheet
- Funded into 2027 readouts. Cash was $797.8 million at June 30 after a $153.2 million quarterly loss.
- Main risk
- Single-asset concentration. All value now sits on IMVT-1402, in markets where argenx and others are already selling FcRn drugs.
- Watch next
- Arthritis update first. The difficult-to-treat RA program update is due in the second half of 2026, then Graves' and myasthenia data in 2027.
Top news on Immunovant
Questions investors ask
What is aibio.space's Investor Rank for Immunovant?
3 out of 10, our negative view. Cash reaches the 2027 readouts, but the company is down to IMVT-1402 after a phase 3 miss and a lupus miss, in markets with approved FcRn drugs. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What is IMVT-1402?
IMVT-1402, also called imeroprubart, is Immunovant's fully human antibody that blocks the FcRn receptor to lower IgG antibody levels. It is given as a subcutaneous injection and is in trials in Graves' disease, myasthenia gravis, rheumatoid arthritis, CIDP and Sjogren's disease. Source
Why did Immunovant stop batoclimab?
Two phase 3 trials of batoclimab in thyroid eye disease did not meet their primary endpoint in April 2026. Immunovant then discontinued batoclimab in all indications to focus on IMVT-1402. Source
What happened in Immunovant's cutaneous lupus trial?
The 57-patient proof-of-concept study of IMVT-1402 did not reach statistical significance on CLASI-A percent change at week 12. Immunovant said it will stop development in cutaneous lupus. Source
How much cash does Immunovant have?
Immunovant had $797.8 million in cash and cash equivalents at June 30, 2026. It says that provides runway to a potential commercial launch of IMVT-1402 in Graves' disease under its current plan. Source
When will Immunovant report Graves' disease data?
Immunovant expects topline data from its potentially registrational trials of IMVT-1402 in Graves' disease and myasthenia gravis in calendar year 2027. Source
What is Immunovant's market cap?
We do not publish live share prices. In its annual report, Immunovant, Inc. put the market value of shares held by non-affiliates (public float) at $1.25 billion as of Sep 30, 2025. Source
Is Immunovant a smaller reporting company?
SEC records list Immunovant, Inc.'s filer category as: Large accelerated filer. Source
Where is Immunovant headquartered?
SEC records list its business address as 1000 PARK FORTY PLAZA, DURHAM, NC, 27713. Source
When does Immunovant's fiscal year end?
Immunovant, Inc.'s fiscal year ends on March 31, per SEC records. Source
What did Immunovant last file with the SEC?
Its most recent filing in our record is an 8-K filed 2026-09-03. All of its filings are on SEC EDGAR. Source
What was Immunovant called before?
SEC records list these former names: Health Sciences Acquisitions Corp. Source
What industry is Immunovant in?
Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source
Legal and investor matters
Note 10 of the 10-Q for the quarter ended 2026-06-30 (filed 2026-08-06) states that as of 2026-06-30 the company was not party to any material legal proceedings. The 10-K for the year ended 2026-03-31 (filed 2026-05-20) says a securities class action complaint filed in February 2021 alleged Exchange Act violations; the court entered judgment for the defendants in April 2024, and the 10-K says the litigation is concluded. Source
- Financing
Immunovant closes $550 million underwritten offering at $21.00 per share
Immunovant sold 26.2 million shares of common stock in an underwritten offering at $21.00 per share under an underwriting agreement dated 2025-12-10 with Leerink Partners. Roivant Sciences, the company's controlling stockholder, participated. The offering closed on 2025-12-12 with gross proceeds of approximately $550 million before discounts, commissions and expenses.
- Governance
Immunovant chief medical officer leaves in R&D leadership restructuring
Michael Geffner ceased serving as chief medical officer effective 2025-11-21, in connection with the company's restructuring of its R&D leadership structure under CEO Eric Venker. Immunovant entered a separation agreement providing severance under his existing employment agreement and a standard release of claims in favor of the company. He will also provide certain consulting services during the transition.
- Governance
Immunovant CEO Peter Salzmann and CFO Renee Barnett depart
Peter Salzmann retired as chief executive officer effective 2025-04-20 and left the board effective 2025-04-18. Renee Barnett ceased serving as chief financial officer on 2025-04-20. The company entered a separation agreement with Salzmann providing severance under his existing employment agreement. The board appointed Eric Venker CEO effective 2025-04-21.
- Financing
Immunovant agrees to $450 million private placement including Roivant
On 2025-01-13 Immunovant entered a share purchase agreement under which institutional accredited investors, including Roivant Sciences, would buy 22,500,000 shares of common stock at $20.00 per share. Expected gross proceeds were approximately $450 million, with closing expected on or about 2025-01-15. The company said it would use net proceeds for pipeline development, working capital and general corporate purposes.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| IMVT-1402 (imeroprubart) | Graves' disease | Potentially registrational trial; topline data expected calendar 2027 Source |
| IMVT-1402 | Myasthenia gravis | Potentially registrational trial; topline data expected calendar 2027 Source |
| IMVT-1402 | Difficult-to-treat rheumatoid arthritis | Potentially registrational trial; open-label week-16 data reported; update expected second half of 2026 Source |
| IMVT-1402 | CIDP and Sjogren's disease | Potentially registrational trials; topline data expected calendar 2028 Source |
| IMVT-1402 | Cutaneous lupus erythematosus | Proof-of-concept trial missed primary endpoint; development stopped (Sept. 2026) Source |
Stock chart
SEC filings and registration
- SEC name
- Immunovant, Inc.
- CIK
- 1764013
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- IMVT (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- March 31
- Filer category
- Large accelerated filer
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Phone
- 917-410-3120
- Shares outstanding
- 206,552,682 as of 2026-08-03 (10-Q filed 2026-08-06)
- Former names
- Health Sciences Acquisitions Corp
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction